Although Y‐CD34+ mice exhibit the greatest improvement in outcome, old CD34+ cells appear to offer some benefits as cardiac function was significantly greater compared to CD34− mice at 4 weeks post‐MI. This evidence concerns the gene CD34 and myocardial infarction.